

18 January 2016

### February 2016 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **February 2016** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

#### New listings

- Dimethyl fumarate (Tecifidera) cap 120 mg (p'code 2493004) and 240 mg (p'code 2493012) – Special Authority – Retail pharmacy, wastage claimable
- Etoposide (Rex Medical) inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist (p'code 2480913)
- Levetiracetam (Everet) tab 250 mg (p'code 2479532), 500 mg (p'code 2479540), 750 mg (p'code 2479559) and 1,000 mg (p'code 2479567)
- Melphalan (Mylan Melphalan) inj 50 mg – PCT only – Specialist, Section 29, wastage claimable (p'code 2494353)
- Pharmacy services (BSF Apo-Mirtazapine) brand switch fee – may only be claimed once per patient (p'code 2493489)
- Rizatriptan (Rizamelt) tab orodispersible 10 mg, 12 tab pack size (p'code 2494213)
- Teriflunomide (Aubagio) tab 14 mg – Special Authority – Retail pharmacy, wastage claimable (p'code 2494418)

#### Changes to restrictions, chemical names and presentations

- Bee venom allergy treatment (Venomil) maintenance kit – 6 vials 120 mcg freeze dried venom, 3 diluent 1.8 ml – amended presentation description
- Ezetimibe (Ezemibe) tab 10 mg – removal of Brand Switch Fee
- Ezetimibe with simvastatin (Zimybe) tab 10 mg with simvastatin 10 mg, 20 mg, 40 mg and 80 mg – removal of Brand Switch Fee
- Fingolimod (Gilenya) cap 0.5 mg – amended Special Authority criteria
- Mirtazapine (Apo-Mirtazapine) tab 30 mg and 45 mg – addition of Brand Switch Fee
- Natalizumab (Tysabri) inj 20 mg per ml, 15 ml vial – amended Special Authority criteria
- Other Multiple Sclerosis Treatment (glatiramer acetate, interferon beta-1-alpha and interferon beta-1-beta) – amended Special Authority criteria
- Standard supplements – amended Special Authority criteria
- Wasp venom allergy treatment (Venomil) treatment kit (paper wasp venom) – 6 vials 120 mcg freeze dried venom, and treatment kit (yellow jacket venom) – 6 vials 120 mcg freeze dried venom – amended presentation description

#### Increased subsidy

Chemical	Presentation	Fully subsidised brands
Amoxicillin with clavulanic acid	Grans for oral liq amoxicillin 125 mg with clavulanic acid 31.25 mg per 5 ml Grans for oral liq amoxicillin 250 mg with clavulanic acid 62.5 mg per 5 ml	Augmentin
Sodium cromoglycate	Powder for inhalation, 20 mg per dose Cap 100 mg	Intal Spincaps Nalcrom

**Decreased subsidy**

<b>Chemical</b>	<b>Presentation</b>	<b>Fully subsidised brands</b>	<b>Partially subsidised brands</b>
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml and 2 ml ampoules	Max Health	
Desferrioxamine mesilate	inj 500 mg vial	Desferal*	Hospira
Doxorubicin hydrochloride	Inj 1 mg for ECP	Baxter	
Glycopyrronium bromide	Inj 200 mcg per ml, 1 ml ampoule	Max Health	
Nystatin	Oral liq 100,000 u per ml	m-Nystatin* Nilstat	
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml and 2 ml ampoules	OxyNorm*	Oxycodone Orion

\* no subsidy changes for these brands for 1 February 2016.